Navigation Links
Plasma produces KO cocktail for MRSA
Date:11/26/2009

MRSA (methicillin-resistant Staphylococcus Aureus) and other drug-resistant bacteria could face annihilation as low-temperature plasma prototype devices have been developed to offer safe, quick, easy and unfailing bactericidal cocktails.

Two prototype devices have been developed: one for efficient disinfection of healthy skin (e.g. hands and feet) in hospitals and public spaces where bacteria can pose a lethal threat; and another to shoot bacteria-killing agents into infested chronic wounds and enable a quicker healing process.

Two papers published today, Thursday 26 November, as part of a selection of papers on Plasma Medicine in New Journal of Physics (co-owned by the Institute of Physics and German Physical Society), demonstrate how far the design of equipment to harness the bacteria-killing power of low-temperature plasma has come.

Plasma, oft called the fourth state of matter after solid, liquid and gas, is defined by its ionized state. In space, stars are made up of high-energy plasma and, on Earth, it is researchers in high-energy plasma that are making significant strides towards limitless energy from nuclear fusion. The high energy of plasma stems from some atoms or molecules in a gas being stripped of their electrons, resulting in a mix of ionized and neutral species.

Also on Earth, scientists have been working on low-temperature and atmospheric-pressure plasma and have found applications in a range of industries, from plastic bag production to the manufacturing of streetlamps and semiconductor circuits.

In a low-temperature plasma, unlike its high-temperature counterparts, the temperature of ions and neutral particles stays low. The 'recipe' for producing such plasmas is simple: the fraction of atoms (molecules) that are ionized and therefore are hot is so low that collisions with cold neutral atoms (molecules) quickly reduce their temperature again. The analogy of adding a drop of hot water to a bucket of cold water gives a sense of how low-temperature plasma physicists are able to create plasmas without dramatically increasing the temperature of the overall molecules.

In medicine, low-temperature plasma is already used for the sterilization of surgical instruments as plasma works at the atomic level and is able to reach all surfaces, even the interior of hollow needle ends. Its ability to disinfect is due to the generation of biologically active bactericidal agents, such as free radicals and UV light, which can be delivered to specific locations. It is research into how and why these biologically active agents are generated that has led to the construction of medically invaluable devices.

One research group from the Max Planck Institute for Extraterrestrial Physics has built and trialed a device which is capable of disinfecting human skin safely and quickly (within seconds), annihilating drug-resistant kinds of bacteria that currently cause approximately 37 000 deaths from hospital induced infections every year in EU countries.

On the current disinfection challenge that medical staff face, and that their device will overcome, the researchers write, "The surgeons' disinfection procedure hand rubbing (3 minutes) or hand scrubbing (5 minutes) has to be repeated many times a day, with a number of negative side-effects arising from the mechanical irritation, chemical and, possibly, allergic stress for the skin. For the hospital staff, the issue of hand disinfection is equally daunting. Over a typical working day, some 60 to 100 disinfections (in principle) are necessary each requiring 3 minutes i.e. a total of 3 to 5 hours!"

The new plasma devices under development cut this down dramatically to around ten minutes a day. In addition, only electricity is needed, no fluids or containers.

Another device, an 'argon plasma torch', was developed by this group, together with ADTEC Plasma Technology Ltd in Japan, specifically for disinfecting chronic non-healing wounds. One advantage of the 'argon plasma torch' comes from regulating densities of biologically-active agents which are designed to ensure that the plasma is deadly for bacteria but harmless for human cells.

Cell biological studies, conducted together with partners from the Institute of Pathology, Technical University of Munich, are reported and interpreted in terms of chemical reactions which work differently in bacterial and human cells deadly to the bacteria and supporting cell regeneration in human cells.

After successful trials that show how plasma can be manipulated to very beneficial ends, these researchers write, "One can treat plasmas like a medical cocktail, which contains new and established agents that can be applied at the molecular level to cells in prescribed intensities and overall doses."

This work represents a first step in the direction of 'plasma pharmacology', a step along a path that will require considerable research efforts to harness the full potential of this new field of 'plasma medicine'.

Both research papers describe the mechanics of their trials, the safety concerns they endeavour to overcome, the remarkable bactericidal effect they have successfully achieved, and the positive cell regeneration effects that can be stimulated using plasmas.


'/>"/>

Contact: Joe Winters
joseph.winters@iop.org
44-207-470-4815
Institute of Physics
Source:Eurekalert

Related biology news :

1. Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds
2. How Toxoplasma gondii gets noticed
3. New study shows Dermytol produces pronounced decrease in malignant melanoma tumor volume
4. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
5. Ethanol byproduct produces green results
6. Obscure fungus produces diesel fuel components
7. Researchers describe implausible chemistry that produces herbicidal compound
8. Wastewater produces electricity and desalinates water
9. UC Davis challenge produces a better air conditioner
10. Accidental discovery produces durable new blue pigment for multiple applications
11. Switchgrass produces biomass efficiently
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... features a variety of fracture-specific plating options designed to address fractures of the ... fracture fixation solutions. , The Acumed Ankle Plating System 3 is composed of ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens say they ... may be hampering the research that could lead to one good one. Surviving Mesothelioma ... it now. , The team evaluated 98 mesothelioma patients who got ...
(Date:5/25/2016)... Haven, Connecticut (PRWEB) , ... May 25, 2016 ... ... that the U.S. Food and Drug Administration (FDA) has granted the company’s orphan ... is the company’s second orphan drug designation granted by the FDA. , ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an ... and entrepreneurs, held The Future of San Diego Life Science event at the Estancia ... science community attended the event with speakers Dr. Rich Heyman, former CEO of Aragon ...
Breaking Biology Technology: